Marijuana and its major psychotropic component, Δ9-tetrahydrocannabinol, stimulate appetite and increase body weight in wasting syndromes, suggesting that the CB1 cannabinoid receptor and its endogenous ligands, the endocannabinoids, are involved in controlling energy balance. The endocannabinoid system controls food intake via both central and peripheral mechanisms, and it may also stimulate lipogenesis and fat accumulation. Here we discuss the multifaceted regulation of energy homeostasis by endocannabinoids, together with its applications to the treatment of eating disorders and metabolic syndromes.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Signal Transduction and Targeted Therapy Open Access 28 August 2022
The endocannabinoid system in zebrafish and its potential to study the effects of Cannabis in humans
Laboratory Animal Research Open Access 22 February 2022
The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling
Cellular and Molecular Life Sciences Open Access 10 January 2020
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Gaoni, Y. & Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646–1647 (1964).
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. & Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564 (1990).
Howlett, A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 68–69, 619–631 (2002).
Devane, W.A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992).
Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90 (1995).
Sugiura, T. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–97 (1995).
Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298–5305 (2004).
Bisogno, T. et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463–468 (2003).
Cravatt, B.F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83–87 (1996).
Dinh, T.P. et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99, 10819–10824 (2002).
Di Marzo. V., Bifulco, F. and De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771–784 (2004).
Williams, C.M., Rogers, P.J. & Kirkham, T.C. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol. Behav. 65, 343–346 (1998).
Williams, C.M. & Kirkham, T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl.) 143, 315–317 (1999).
Hao, S., Avraham, Y., Mechoulam, R. & Berry, E.M. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur. J. Pharmacol. 392, 147–156 (2000).
Rinaldi-Carmona, M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240–244 (1994).
Simiand, J., Keane, M., Keane, P.E. & Soubrie, P., Sr. 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. 9, 179–181 (1998).
Colombo, G. et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63, PL113–PL117 (1998).
Rowland, N.E. Mukherjee. M. & Robertson, K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl.) 159, 111–116 (2001).
Williams, C.M. & Kirkham, T.C. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol. Biochem. Behav. 71, 333–340 (2002).
Werner, N.A. & Koch, J.E. Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res. 967, 290–292 (2003).
Rinaldi-Carmona, M. et al. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 310, 905–914 (2004).
Chambers, A.P., Sharkey, K.A. & Koopmans, H.S. Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol. Behav. 82, 863–869 (2004).
Di Marzo, V. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822–825 (2001).
Jamshidi, N. & Taylor, D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 134, 1151–1154 (2001).
Kirkham, T.C., Williams, C.M., Fezza, F. & Di Marzo, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136, 550–557 (2002).
Tucci, S.A., Rogers, E.K., Korbonits, M. & Kirkham, T.C. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br. J. Pharmacol. 143, 520–533 (2004).
McLaughlin, P.J. et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav. Pharmacol. 14, 583–588 (2003).
De Vry, J., Schreiber, R., Eckel, G. & Jentzsch, K.R. Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur. J. Pharmacol. 483, 55–63 (2004).
Thornton-Jones, Z.D., Vickers, S.P. & Clifton, P.G. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology (Berl.) advance online publication, January 2005 (10.1007/s00213-004-2047-8).
Higgs, S., Williams, C.M. & Kirkham, T.C. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology (Berl.) 165, 370–377 (2003).
Cota, D. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423–431 (2003).
Horvath, T.L. Endocannabinoids and the regulation of body fat: the smoke is clearing. J. Clin. Invest. 112, 323–326 (2003).
Di, S., Malcher-Lopes, R., Halmos, K.C. & Tasker, J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 23, 4850–4857 (2003).
Hilairet, S., Bouaboula, M., Carriere, D., Le Fur, G. & Casellas P. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J. Biol. Chem. 278, 23731–23737 (2003).
Poncelet, M., Maruani, J., Calassi, R. & Soubrie, P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci. Lett. 343, 216–218 (2003).
Verty, A.N., McFarlane, J.R., McGregor, I.S. & Mallet, P.E. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145, 3224–3231 (2004).
Verty, A.N., McGregor, I.S. & Mallet, P.E. The dopamine receptor antagonist SCH 23390 attenuates feeding induced by Delta9-tetrahydrocannabinol. Brain Res. 1020, 188–195 (2004).
Duarte, C. et al. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Neuropsychopharmacology 29, 911–920 (2004).
Kirkham, T.C. & Williams, C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl.) 153, 267–270 (2001).
Verty, A.N., Singh, M.E., McGregor, I.S. & Mallet, P.E. The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (Berl.) 168, 314–323 (2003).
Chen, R.Z., Huang, R.R., Shen, C.P., MacNeil, D.J. & Fong, T.M. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res. 999, 227–230 (2004).
Fride, E. The endocannabinoid-CB(1) receptor system in pre- and postnatal life. Eur. J. Pharmacol. 500, 289–297 (2004).
Berrendero, F., Sepe, N., Ramos, J.A., Di Marzo, V. & Fernandez-Ruiz, J.J. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33, 181–191 (1999).
Di Marzo, V. et al. Trick or treat from food endocannabinoids? Nature 396, 636 (1998).
Gomez, R. et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 22, 9612–9617 (2002).
Burdyga, G. et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J. Neurosci. 24, 2708–2715 (2004).
Black, S.C. Cannabinoid receptor antagonists and obesity. Curr. Opin. Investig. Drugs 5, 389–394 (2004).
Vickers, S.P., Webster, L.J., Wyatt, A., Dourish, C.T. & Kennett, G.A. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl.) 167, 103–111 (2003).
Ravinet Trillou, C. et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R345–R353 (2003).
Hildebrandt, A.L., Kelly-Sullivan, D.M. & Black, S.C. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur. J. Pharmacol. 462, 125–132 (2003).
Poirier, B. et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 7, 65–72 (2005).
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M. & Soubrie, P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistence to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28, 640–648 (2004).
Liu, Y.L., Connoley, I.P., Wilson, C.A. & Stock, M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. Relat. Metab. Disord. 29, 183–187 (2005).
Bensaid, M. et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908–914 (2003).
Osei-Hyiaman, D. et al. Endocannabinoid action at hepatic CB1 receptors regulates fatty acid synthesis: role in diet-induced obesity. J. Clin. Invest. (in the press).
Qi, Y. et al. Adiponectin acts in the brain to decrease body weight. Nat. Med. 10, 524–529 (2004).
Carai, M.A., Colombo, G. & Gessa, G.L. Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant). Eur. J. Pharmacol. 494, 221–224 (2004).
Berger, A. et al. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc. Natl. Acad. Sci. USA 98, 6402–6406 (2001).
Hanus, L. et al. Short-term fasting and prolonged semi-starvation have opposite effects on 2-AG levels in mouse brain. Brain Res. 983, 144–151 (2003).
Matias, I. et al. Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels. Cell. Mol. Life Sci. 60, 382–389 (2003).
Watanabe, S., Doshi, M. & Hamazaki, T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot. Essent. Fatty Acids 69, 51–59 (2003).
Monteleone, P. et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge eating disorder, but not in bulimia nervosa. Neuropsychopharmacology (in the press).
Pertwee, R.G. Inverse agonism and neutral antagonism at cannabinoid CB(1) receptors. Life Sci. 76, 1307–1324 (2005).
Maccarrone, M., Di Rienzo, M., Finazzi-Agro, A. & Rossi, A. Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J. Biol. Chem. 278, 13318–13324 (2003).
Sipe, J.C., Waalen, J., Gerber, A. & Beutler, E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J. Obesity, advance online publication 5 April 2005 (10.1038/sj.ijo.0802954).
The authors declare competing financial interests (see the Nature Neuroscience website for details).
About this article
Cite this article
Di Marzo, V., Matias, I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8, 585–589 (2005). https://doi.org/10.1038/nn1457
This article is cited by
The endocannabinoid system in zebrafish and its potential to study the effects of Cannabis in humans
Laboratory Animal Research (2022)
Signal Transduction and Targeted Therapy (2022)
Reviews in Endocrine and Metabolic Disorders (2022)
First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18F-T-401
European Journal of Nuclear Medicine and Molecular Imaging (2022)
Endocannabinoid signaling of homeostatic status modulates functional connectivity in reward and salience networks